Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

Cancer

Volumn 118, Issue 5, 2012, Pages 1252-1259

  Barrios, Carlos H ^a   Hernandez Barajas, David ^b   Brown, Michael P ^c   Lee, Se Hoon ^d   Fein, Luis ^e   Liu, Jin Hwang ^f   Hariharan, Subramanian ^g   Martell, Bridget A ^g   Yuan, Jinyu ^g   Bello, Akintunde ^g   Wang, Zhixiao ^h   Mundayat, Rajiv ^g   Rha, Sun Young ⁱ  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d Seoul National University Hospital   (South Korea)

^e Centro Oncologico de Rosario   (Argentina)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g Pfizer Ltd   (United States)

^h PFIZER INC   (United States)

ⁱ Yonsei University College of Medicine   (South Korea)

Author keywords

continuous dosing; metastastic; renal cell carcinoma; sunitinib; treatment naive

Indexed keywords

DRUG METABOLITE; N DEETHYLSUNITINIB; PROTEIN; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER MORTALITY; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY KIDNEY SYMPTOM INDEX; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS FATIGUE; GENERAL CONDITION DETERIORATION; HAND FOOT SYNDROME; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RATING SCALE; SIDE EFFECT; SKIN DEFECT; SKIN DISCOLORATION; STEADY STATE; STOMACH HEMORRHAGE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION; YELLOW SKIN;

ADULT; AGED; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PYRROLES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84863116418     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26440     Document Type: Article

References (28)

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
2. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111. (Pubitemid 350296300)
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27: 3312-3318.
4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281. (Pubitemid 46849157)
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124. (Pubitemid 46089672)
6. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
7. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-5428.
8. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2: 471-478.
9. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337. (Pubitemid 36109749)
10. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 1: 3597-3605. (Pubitemid 36857948)
11. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
12. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 4068-4075.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
14. Cella DF,. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Evanston, IL: Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
15. Cella D, Yount S, Du H, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol. 2006; 4: 191-199. (Pubitemid 43890980)
16. Cella DF, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Sympton Manage. 2002; 24: 547-561. (Pubitemid 36120443)
17. Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health. 2007; 10: 285-293. (Pubitemid 47077253)
18. Cella D, Lai J, Chang C, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002; 94: 528-538. (Pubitemid 34081385)
19. Motzer R, Michaelson M, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24. (Pubitemid 46630489)
20. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-2524. (Pubitemid 43854967)
21. Li XS, Song Y, Gong K, et al. Clinical study of sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience. Zhonghua Wai Ke Za Zhi. 2010; 48: 375-377.
22. Tomita Y, Shinohara N, Yuasa T, et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2010; 40: 1166-1172.
23. Yoo C, Kim JE, Lee JL, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010; 40: 980-985.
24. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009; 45: 1959-1968.
25. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer. 2009; 101: 1543-1548.
26. DePrimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5: 32.
27. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH,. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009; 9: 82.
28. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized Phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 vs continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma (Renal EFFECT Trial). Oral presentation at the 2011 American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, FL, USA, February 17-19, 2011 (abstract 308)